(APLT) Applied Therapeutics - Overview

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US03828A1016

Stock: Drug Candidate, Phase 3, Galactosemia, Cardiomyopathy, Neuropathy

Total Rating 17

Risk 67

Buy Signal 0.00

Biotechnology » Biotechnology
Age: 6.7y

Market Cap: 15m
Avg Trading Vol: 663K USD

ATR: 13.02%
Peers RS (IBD): 0.10

EPS (Earnings per Share)

EPS CAGR: 141.46%
EPS Trend: 65.6%

Last SUE: 0.33
Qual. Beats: 0

Revenue

Rev. CAGR: 12.92%
Rev. Trend: -0.5%

Last SUE: 0.22
Qual. Beats: 0

Risk 5d forecast
Volatility	152%
Relative Tail Risk	-32.2%

Reward TTM
Sharpe Ratio	0.10
Alpha	-101.82

Character TTM
Beta	1.389
Beta Downside	1.868

Drawdowns 3y
Max DD	99.10%
CAGR/Max DD	-0.55

Description: APLT Applied Therapeutics December 22, 2025

Applied Therapeutics, Inc. (NASDAQ:APLT) is a clinical-stage biotech focused on novel therapies for high-unmet-need diseases in the U.S., with its lead candidate AT-007 having completed Phase 3 in healthy adults for galactosemia and now advancing in pediatric studies and additional rare-enzyme indications.

Key operational metrics and sector context: (1) APLT reported approximately $45 million of cash and short-term investments in its most recent 10-Q, giving it runway through late 2025 under current burn rates; (2) The global rare-disease drug market is projected to surpass $300 billion by 2030, providing a sizable addressable market for AT-007 and related pipelines; (3) Diabetic cardiomyopathy, the target of AT-001 (Phase 3), represents a $10 billion+ therapeutic opportunity as diabetes prevalence rises and cardiometabolic complications drive demand for disease-modifying treatments.

For a deeper quantitative assessment, you may find ValueRay’s platform useful.

Piotroski VR‑10 (Strict, 0-10) 1.0

Net Income: -18.1m TTM > 0 and > 6% of Revenue
FCF/TA: -2.53 > 0.02 and ΔFCF/TA -175.9 > 1.0
NWC/Revenue: -124.9% < 20% (prev 56.40%; Δ -181.3% < -1%)
CFO/TA -2.53 > 3% & CFO -86.8m > Net Income -18.1m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 0.96 > 1.5 & < 3
Outstanding Shares: last quarter (145.6m) vs 12m ago 0.84% < -2%
Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin)
Asset Turnover: 1.42% > 50% (prev 9.38%; Δ -7.96% > 0%)
Interest Coverage Ratio: -1.22 > 6 (EBITDA TTM -67.5m / Interest Expense TTM -82.5m)

Altman Z'' -15.00

A: -0.04 (Total Current Assets 31.7m - Total Current Liabilities 32.9m) / Total Assets 34.4m
B: -18.51 (Retained Earnings -636.4m / Total Assets 34.4m)
C: -1.43 (EBIT TTM -100.6m / Avg Total Assets 70.5m)
D: -18.21 (Book Value of Equity -636.3m / Total Liabilities 34.9m)
Altman-Z'' Score: -89.31 = D

What is the price of APLT shares?

As of February 07, 2026, the stock is trading at USD 0.10 with a total of 0 shares traded.
Over the past week, the price has changed by +0.19%, over one month by -2.83%, over three months by -86.22% and over the past year by -83.09%.

Is APLT a buy, sell or hold?

Applied Therapeutics has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy APLT.

StrongBuy: 2
Buy: 0
Hold: 2
Sell: 0
StrongSell: 0

What are the forecasts/targets for the APLT price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	0.3	150%
Analysts Target Price	0.3	150%
ValueRay Target Price	0.1	-30%

APLT Fundamental Data Overview February 03, 2026

P/S = 14.8341
P/B = 7.7151
Revenue TTM = 999.0k USD
EBIT TTM = -100.6m USD
EBITDA TTM = -67.5m USD
Long Term Debt = 2.50m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 467.0k USD (from shortTermDebt, last quarter)
Debt = 2.50m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -9.45m USD (from netDebt column, last quarter)
Enterprise Value = 5.39m USD (14.8m + Debt 2.50m - CCE 11.9m)
Interest Coverage Ratio = -1.22 (Ebit TTM -100.6m / Interest Expense TTM -82.5m)
EV/FCF = -0.06x (Enterprise Value 5.39m / FCF TTM -86.8m)
FCF Yield = -1612 % (FCF TTM -86.8m / Enterprise Value 5.39m)
FCF Margin = -8693 % (FCF TTM -86.8m / Revenue TTM 999.0k)
Net Margin = -1816 % (Net Income TTM -18.1m / Revenue TTM 999.0k)
Gross Margin = -1678 % ((Revenue TTM 999.0k - Cost of Revenue TTM 17.8m) / Revenue TTM)
Gross Margin QoQ = 100.0% (prev none%)
Tobins Q-Ratio = 0.16 (Enterprise Value 5.39m / Total Assets 34.4m)
Interest Expense / Debt = 28.84% (Interest Expense 721.0k / Debt 2.50m)
Taxrate = 21.0% (US default 21%)
NOPAT = -79.5m (EBIT -100.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 0.96 (Total Current Assets 31.7m / Total Current Liabilities 32.9m)
Debt / Equity = -4.46 (negative equity) (Debt 2.50m / totalStockholderEquity, last quarter -561.0k)
Debt / EBITDA = 0.14 (negative EBITDA) (Net Debt -9.45m / EBITDA -67.5m)
Debt / FCF = 0.11 (negative FCF - burning cash) (Net Debt -9.45m / FCF TTM -86.8m)
Total Stockholder Equity = 27.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -25.74% (Net Income -18.1m / Total Assets 34.4m)
RoE = -65.63% (Net Income TTM -18.1m / Total Stockholder Equity 27.6m)
RoCE = -333.9% (out of range, set to none) (EBIT -100.6m / Capital Employed (Equity 27.6m + L.T.Debt 2.50m))
RoIC = -287.7% (out of range, set to none) (NOPAT -79.5m / Invested Capital 27.6m)
WACC = 12.73% (E(14.8m)/V(17.3m) * Re(11.03%) + D(2.50m)/V(17.3m) * Rd(28.84%) * (1-Tc(0.21)))
Discount Rate = 11.03% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 31.45%
Fair Price DCF = unknown (Cash Flow -86.8m)
EPS Correlation: 65.62 | EPS CAGR: 141.5% | SUE: 0.33 | # QB: 0
Revenue Correlation: -0.51 | Revenue CAGR: 12.92% | SUE: 0.22 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.12 | Chg30d=+0.045 | Revisions Net=+1 | Analysts=2
EPS next Year (2026-12-31): EPS=-0.40 | Chg30d=+0.137 | Revisions Net=+3 | Growth EPS=+25.9% | Growth Revenue=+25.0%

Additional Sources for APLT Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Fund Manager Positions: Dataroma | Stockcircle